LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).
1 finding from 1 review
- Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting… 2015 · Cochrane Headline outcomes onlyOR 0.72 [0.18, 2.92]4 studies · 2022 participantsVery low